📢 What This Document Is

This is an 8-K filing, which is like a company's official "news flash" to the stock market. CervoMed is using it to announce that it will be presenting major updates about its key drug, neflamapimod, at important medical conferences. It's a way to build credibility and share progress with investors and the scientific community.

🧠 What The Company Does

👉 In simple terms, CervoMed is a small, early-stage biotech company trying to develop the first-ever approved medicine for a specific type of dementia.

The company is focused on "age-related brain disorders." Its main hope is a drug called neflamapimod (pronounced nef-la-MAP-i-mod), which is a pill designed to calm harmful inflammation and dysfunction in the brain. They are targeting this drug primarily at Dementia with Lewy Bodies (DLB).

🧪 The Disease & The Drug

The Problem (DLB): DLB is the second most common progressive dementia after Alzheimer's. It affects millions worldwide but currently has no approved treatments in the US or Europe. This represents a huge unmet medical need.

The Potential Solution (Neflamapimod): This investigational drug works by inhibiting a specific enzyme (p38 MAP kinase) that drives neuroinflammation and synaptic dysfunction—problems that are central to DLB. Think of it as trying to repair the communication lines (synapses) between brain cells that are being damaged by inflammation.

🚀 Key Updates & Clinical Findings

CervoMed is sharing several crucial pieces of progress:

• Phase 3 Trial Design is Finalized: The company has completed the blueprint for its pivotal Phase 3 trial, which is the final large study needed before seeking drug approval. They have aligned this design with global regulatory authorities.
• New MRI Data Shows Promise: New analyses from the previous Phase 2b trial are encouraging. They suggest neflamapimod may reduce atrophy (shrinking) in a critical brain region called the basal forebrain. This is important because atrophy in this area is linked to cognitive decline in DLB.
• Biomarker Insights: The CEO highlighted a blood biomarker (plasma GFAP) that seems to track with the disease and, importantly, shows a response to neflamapimod treatment. This could be a valuable tool for measuring if the drug is working in future trials.
• Phase 3 Trial Timeline: The company plans to initiate the global Phase 3 trial in the second half of 2026, pending funding.

📅 Key Dates & Events

• April 7, 2026: Presentation at the Lewy Body Dementia Association Annual Meeting in Atlanta.
• April 22, 2026: Poster presentation with more MRI data at the American Academy of Neurology Annual Meeting in Chicago.
• H2 2026: Planned start of the Phase 3 clinical trial.

⚖️ The Big Picture: Strengths & Risks

👍 Strengths / Opportunities:

• Massive Unmet Need: Being potentially the first-to-market with an approved DLB treatment is a huge opportunity.
• Scientific Rationale: The drug targets a core disease mechanism (synaptic dysfunction), and early clinical and biomarker data are consistently positive.
• Clear Path Forward: They have a finalized, regulator-aligned Phase 3 design and a clear timeline.

⚠️ Risks / Challenges:

• Execution Risk: They must successfully run a large, complex global Phase 3 trial. This is expensive and not guaranteed to succeed.
• Funding Need: The trial start is "subject to available funding." This is a critical hurdle for a clinical-stage company.
• Competition: The brain disease field is active, and other companies are also pursuing DLB treatments.
• Binary Outcome: The Phase 3 trial will be a "make-or-break" moment. Failure would be a major setback.

🧠 The Analogy

CervoMed is like a team building the first bridge across a wide, important river (treating DLB). They've finished designing the bridge (finalized Phase 3 plan), shown promising blueprints and strong support pillars from their earlier model (Phase 2b data & MRI findings), and now need to secure the funding and contracts to actually start construction (initiate Phase 3 trial).

🧩 Final Takeaway

CervoMed is advancing its promising Alzheimer's-alternative brain drug, neflamapimod, toward a final-stage clinical trial for Lewy Body Dementia. The update signals confidence in their scientific data and a clear, regulator-aligned path forward, but their success now hinges on securing funding and executing the large, pivotal Phase 3 study in 2026.

Contacts: Media: Biongage Communications | [email protected] | 202-330-3431 Investor Relations: Argot Partners | [email protected] | 212-600-1902